<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS140201</article-id>
<article-id pub-id-type="doi">10.1101/2021.11.24.469775</article-id>
<article-id pub-id-type="archive">PPR425063</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Atazanavir is a competitive inhibitor of SARS-CoV-2 M<sup>pro</sup>, impairing variants replication <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Augusto Chaves</surname>
<given-names>Otávio</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Sacramento</surname>
<given-names>Carolina Q</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Ferreira</surname>
<given-names>André C</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Mattos</surname>
<given-names>Mayara</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fintelman-Rodrigues</surname>
<given-names>Natalia</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Temerozo</surname>
<given-names>Jairo R</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pinto</surname>
<given-names>Douglas Pereira</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>da Silveira</surname>
<given-names>Gabriel PE</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>da Fonseca</surname>
<given-names>Laís Bastos</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pereira</surname>
<given-names>Heliana Martins</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carlos</surname>
<given-names>Aluana Santana</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>d’Ávila</surname>
<given-names>Joana da Costa Pinto</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Viola</surname>
<given-names>João PB</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Monteiro</surname>
<given-names>Robson Q</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vazquez</surname>
<given-names>Leonardo</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bozza</surname>
<given-names>Patrícia T</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Castro-Faria-Neto</surname>
<given-names>Hugo Caire</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Souza</surname>
<given-names>Thiago Moreno L</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil</aff>
<aff id="A2">
<label>2</label>National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil</aff>
<aff id="A3">
<label>3</label>Preclinical Research Laboratory, Universidade Iguaçu - UNIG, Nova Iguaçu, RJ, Brazil</aff>
<aff id="A4">
<label>4</label>Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil</aff>
<aff id="A5">
<label>5</label>National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil</aff>
<aff id="A6">
<label>6</label>Laboratory of Pharmacokinetics, Vice Presidency of Research, and Innovation in Health - Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil</aff>
<aff id="A7">
<label>7</label>Program of Immunology and Tumor Biology, Brazilian National Cancer Institute (INCA), Rua André Cavalcanti 37, 5<sup>th</sup> floor, Centro, Rio de Janeiro, Brazil</aff>
<aff id="A8">
<label>8</label>Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Correspondences: <email>otavioaugustochaves@gmail.com</email> (O.A.C.), <email>tmoreno@cdts.fiocruz.br</email> (T.M.L.S.)</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>27</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="preprint">
<day>24</day>
<month>11</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">Atazanavir (ATV) has already been considered as a potential repurposing drug to 2019 coronavirus disease (COVID-19), however, there are controversial reports on its mechanism of action and effectiveness as anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Through the pre-clinical chain of experiments: enzymatic, molecular docking, cell-based, and <italic>in vivo</italic> assays, it is demonstrated here that both SARS-CoV-2 B.1 lineage and variant of concern gamma are susceptible to this antiretroviral. Enzymatic assays and molecular docking calculations showed that SARS-CoV-2 main protease (M<sup>pro</sup>) was inhibited by ATV, with Morrison’s inhibitory constant (Ki) 1.5-fold higher than boceprevir (GC376, a positive control). ATV was a competitive inhibition, increasing the M<sup>pro</sup>’s Michaelis-Menten (K<sub>m</sub>) more than 6-fold. Cell-based assays indicated that SARS-CoV-2 gamma is more susceptible to ATV than its predecessor strain B.1. Using oral administration of ATV in mice to reach plasmatic exposure similar to humans, transgenic mice expression in human angiotensin converting enzyme 2 (K18-hACE2) were partially protected against lethal challenge with SARS-CoV-2 gamma. Moreover, less cell death and inflammation were observed in the lung from infected and treated mice. Our studies may contribute to a better comprehension of the M<sup>pro</sup>/ATV interaction, which could pave the way to the development of specific inhibitors of this viral protease.</p>
</abstract>
<kwd-group>
<kwd>SARS-CoV-2</kwd>
<kwd>COVID-19</kwd>
<kwd>repurposing drugs</kwd>
<kwd>atazanavir</kwd>
<kwd>protease inhibitor</kwd>
<kwd>pharmacokinetics</kwd>
<kwd>molecular docking</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p id="P2">The 2019 coronavirus disease (COVID-19) was firstly reported in Wuhan (China) and its etiological agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread globally into the second pandemic of the 21<sup>st</sup> century, after influenza A(H1N1) pandemic in 2009. SARS-CoV-2 continuously circulate, even among individuals with preexisting immunity, and caused about 258 million confirmed cases along with 5.16 million deaths worldwide [<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R5">5</xref>]. SARS-CoV-2 variants of concern (VoC) might escape the humoral immune response to natural infection or vaccination [<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref>], which reinforces the necessity of specific antiviral treatments. After almost a two-year effort in the repurposing of clinically approved drugs, limited benefit for COVID-19 patients have been demonstrated [<xref ref-type="bibr" rid="R5">5</xref>]. Thus, it is necessary to improve the pre-clinical characterization of repurposed drugs to rationalize further clinical studies, in terms of posology and susceptibility of VoC, and learn from their interactions with the viral target enzyme.</p>
<p id="P3">We have previously described that atazanavir (ATV), a clinically approved human immunodeficiency virus (HIV) protease inhibitor [<xref ref-type="bibr" rid="R6">6</xref>], is endowed with anti-SARS-CoV-2 activity [<xref ref-type="bibr" rid="R7">7</xref>]. Although we described early in the pandemic outbreak the ATV’s activity against SARS-CoV-2, by <italic>in silico</italic> and cell-based assays (in Vero-E6 and A549 cell lines), proper characterization of its enzymatic target, pharmacology on type II pneumocytes (the most affect cell in severe COVID-19) and antiviral activity in infected mice have not been described. Nevertheless, numerous clinical trials were initiated for out- and in-patients with COVID-19 to test ATV combined or not with other commercial drugs, such as ritonavir or dexamethasone [<xref ref-type="bibr" rid="R7">7</xref>–<xref ref-type="bibr" rid="R9">9</xref>], however no definitive response emerged from these clinical trials yet.</p>
<p id="P4">Studies reconfirmed, by bioinformatics and basic enzymatic inhibition curves, that ATV targets SARS-CoV-2 major protease (M<sup>pro</sup>), an enzyme responsible for the cleavage of eleven sites of the viral polyprotein, a key-step in virus life cycle [<xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R11">11</xref>]. The development of PAXLOVID™ from Pfizer and its clinical efficacy of reduce hospitalization by 80% reconfirms that M<sup>pro</sup> is a very important druggable target [<xref ref-type="bibr" rid="R12">12</xref>]. Thus, other drugs that target this enzyme deserve a more detailed characterization, to provide insight on pharmacophoric regions for next generation of anti-COVID-19 antivirals.</p>
<p id="P5">Anti-M<sup>pro</sup> from ATV has been disputed as controversial depending on assay conditions [<xref ref-type="bibr" rid="R13">13</xref>]. This apparent paradox reinforces that detailed mechanism of action and robust series of pre-clinical experiments should be conducted to shed light on the ATV inhibitory mechanism and the susceptibility of contemporaneous SARS-CoV-2 strains to this drug. Here, we address additional explanations to controversial effects of ATV on M<sup>pro</sup>, characterizing it as a competitive inhibitor of this viral enzyme that requires a catalytic water to be effective. ATV possesses anti-SARS-CoV-2 activity against B.1 and gamma strains on Calu-3 cells, a model of type II pneumocytes. ATV reached the plasma and lungs of treated Swiss-Webster mice and protected SARS-CoV-2-infected transgenic mice expression in human angiotensin converting enzyme 2 (K18-hACE2) from mortality. Moreover, ATV reduced virus-induced inflammation and cell death in bronchoalveolar lavage (BAL), and lung damage in infected and treated animals. This study compiles pre-clinical results that may allow further rationalization of clinical trials against COVID-19.</p>
</sec>
<sec id="S2" sec-type="materials | methods">
<label>2</label>
<title>Materials and Methods</title>
<sec id="S3">
<label>2.1</label>
<title>General materials</title>
<p id="P6">Carboxymethyl cellulose (CMC), <italic>tris</italic>(4-(dimethylamino)phenyl)methylium chloride (crystal violet), formaldehyde, hematoxylin, eosin, phosphate buffer solution (PBS), ethanol, dimethyl sulfoxide (DMSO), ketamine, xylazine, trisodium citrate, calcium chloride (CaCl2), and remdesivir (RDV) were purchased from Sigma-Aldrich/Merck (St. Louis, MO, USA). Atazanavir sulfate (ATV) was kindly donated from <italic>Instituto de Tecnologia de Farmacos</italic>, Farmanguinhos, Rio de Janeiro, Brazil.</p>
</sec>
<sec id="S4">
<label>2.2</label>
<title>Cells and virus</title>
<p id="P7">African green monkey kidney (Vero, subtype E6) and human lung epithelial (Calu-3) cells were cultured in high-glucose Dulbecco’s modified Eagle medium (DMEM - HyClone, Logan, Utah) supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin (P/S - Thermo Fisher Scientific®, Massachusetts, USA), and 10% fetal bovine serum (FBS - HyClone, Logan, Utah). The cells were incubated at 310K in 5 % of carbon dioxide (CO<sub>2</sub>).</p>
<p id="P8">The SARS-CoV-2 B.1 lineage (GenBank #MT710714) and gamma variant (also known as P1 or B.1.1.28 lineage; #EPI_ISL_1060902) were isolated on Vero E6 cells from nasopharyngeal swabs of confirmed cases. All procedures related to virus culture were handled at biosafety level 3 (BSL3) multiuser facility at <italic>Fundação Oswaldo Cruz</italic> (Fiocruz), Rio de Janeiro, Brazil, according to World Health Organization (WHO) guidelines [<xref ref-type="bibr" rid="R14">14</xref>].</p>
</sec>
<sec id="S5">
<label>2.3</label>
<title>Enzymatic assays</title>
<p id="P9">The ATV capacity to inhibit enzymatic velocity of PL<sup>pro</sup> and M<sup>pro</sup> from SARS-CoV-2 was determined by the commercial kit provided by BPS Bioscience® company (catalog number: #79995-1 and #79955-1, respectively) following the procedure and recommendations from literature and manufacturer [<xref ref-type="bibr" rid="R15">15</xref>–<xref ref-type="bibr" rid="R17">17</xref>]. Basically, 100 nM PL<sup>pro</sup> was incubated in 50 mM HEPES pH 7.4, 0.01% Triton X-100 (v/v), 0.1 mg/mL bovine serum albumin (BSA), 2 mM dithiothreitol (DTT) with 25 μM of its substrate (modified peptide Z-RLRGG-AMC with CAS number 167698-69-3) in the presence various concentrations (0-10 μM of ATV or GRL0617 (positive control) for 45-60 minutes. On the other hand, 88.8 nM M<sup>pro</sup> was incubated overnight in reaction buffer (20 mM Tris pH 7.3, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, and 1 μM BSA) containing 25 μM of substrate (modified peptide DABCYL-KTSAVLQSGFRKME-EDANS with CAS number 730985-86-1) and ATV or boceprevir (GC376, positive control), at concentrations ranging from 0 to 10 μM. Fluorescence signal was measured at an emission wavelength of 460 nm with excitation at 360 nm in a GloMax® (Promega) plate reader. Morrison’s inhibitory constant (Ki) was calculated by non-linear regression using GraphPad Prism 9. The Michaelis-Menten plot was conducted for 88.8 nM M<sup>pro</sup> incubated overnight in assay buffer with substrate concentrations varying from 0 to 100 μM in the presence and absence of 2.5 μM of ATV. After fluorescence quantification, the Michaelis-Menten constant (K<sub>m</sub>) and maximum velocity (V<sub>max</sub>) were calculated by non-linear regression using GraphPad Prism 9. The value was presented as mean ± standard deviation (SD).</p>
</sec>
<sec id="S6">
<label>2.4</label>
<title>Molecular docking procedure</title>
<p id="P10">The crystallographic structure of M<sup>pro</sup> was obtained from Protein Data Bank (PDB), with access code 7K40 [<xref ref-type="bibr" rid="R18">18</xref>]. The chemical structure for ATV was built and minimized in terms of energy by Density Functional Theory (DFT) via Spartan’18 software (Wavefunction, Inc., Irvine, CA, USA) [<xref ref-type="bibr" rid="R19">19</xref>]. The molecular docking calculations were performed with GOLD 2020.2 software (Cambridge Crystallographic Data Center Software Ltd., CCDC, CB2 1EZ, UK) [<xref ref-type="bibr" rid="R20">20</xref>]. Hydrogen atoms were added to the protease following tautomeric states and ionization data, which are inferred by the GOLD 2020.2 software at pH 7.4. The number of genetic operations (crossing, migration, mutation) during the search procedure was set as 100,000. Redocking studies were carried out with the crystallographic ligand boceprevir (GC376, PDB code: 7K40), obtaining the lowest root mean square deviation (RMSD) value by ChemPLP function. It was defined 8 radius around the active binding site and the figures were generated with PyMOL Delano Scientific LLC software (DeLano Scientific LLC: San Carlos, CA, USA) [<xref ref-type="bibr" rid="R21">21</xref>].</p>
</sec>
<sec id="S7">
<label>2.5</label>
<title>Yield-reduction assays and virus titration</title>
<p id="P11">Calu-3 cells (2.0 × 10<sup>5</sup> cells/well) were infected with multiplicity of infection (MOI) of 0.1 and 0.001 for SARS-CoV-2 B.1 lineage and MOI of 0.1 for SARS-CoV-2 gamma strain. Infection was performed in 96-well plates (Nalge Nunc Int, Rochester, New York, USA) for 1 h at 37°C in 5 % of CO<sub>2</sub>. Inoculum was removed and cells were incubated different concentrations of ATV (0.00, 0.60, 1.25, 2.50, 5.00, and 10.0 μM) or RDV (0.00, 0.0001, 0.001, 0.01, 0.10, 0.50, 1.0, 5.0, and 10.0, μM) in DMEM with 10% FBS. After 48 h, the supernatants were harvested, and infectious virus titers were quantified by plaque forming assays according to previous publications [<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R23">23</xref>].</p>
<p id="P12">To perform the virus titration, Vero cells (2.0 × 10<sup>4</sup> cell/well) in 96-well plates (Nalge Nunc Int, Rochester, New York, USA) were infected with log-based dilutions of the yield reduction assays` supernatants for 1 h at 37°C in 5% of CO<sub>2</sub>. After the incubation, medium containing 1.8% CMC with 5% FBS was added and incubated at 37°C with 5% CO<sub>2</sub> for 72 h. The cells were fixed with 10% formaldehyde in PBS and stained with a 0.04% solution of crystal violet in 70% methanol. The virus titers were calculated by scoring the plaque-forming unit – (PFU/mL) and a non-linear regression analysis of the dose-response curves was also performed to calculate the 50% effective concentration (EC<sub>50</sub>). All experiments were carried out at least three independent times, including a minimum of two technical replicates in each assay, and each data was analyzed from Prism GraphPad software 8.0 (Windows GraphPad Software, San Diego, California USA). The value was presented as mean ± standard deviation (SD).</p>
</sec>
<sec id="S8">
<label>2.6</label>
<title>Cytotoxic assays</title>
<p id="P13">Vero cells (2.0 × 10<sup>4</sup> cell/well) were treated for 3 days with different concentrations of ATV or RDV (ranging from 1 to 600 μM) as previously described by us [<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R23">23</xref>]. The 50% cytotoxic concentration (CC<sub>50</sub>) was calculated by a non-linear regression analysis from a dose–response curve. All experiments were carried out at least three independent times and each data was analyzed from Prism GraphPad software 8.0 (Windows GraphPad Software, San Diego, California USA). The results were presented as mean ± standard deviation (SD). The selectivity indexes (SI) for ATV and RDV were calculated through the ratio between CC<sub>50</sub> and EC<sub>50</sub> values.</p>
</sec>
<sec id="S9">
<label>2.7</label>
<title>Pharmacokinetic assays</title>
<p id="P14">ATV`s concentration in the plasma and lungs of adult Swiss-Webster mice (8-15 weeks) was evaluated over time. Animals were treated with an oral dose of 60 mg/kg of ATV for 12-time intervals - 00:05, 00:10, 00:20, 00:40, 01:00, 02:00, 03:00, 04:00, 06:00, 08:00, 10:00, and 12:00h. Each treatment group had 5 animals. After these periods of times, total blood and lungs were collected. Plasma was obtained by blood centrifugation at 8,000 x g for 15 minutes. Time zero was obtained by analyzing the matrix pool (blood plasma) of untreated animals. The pharmacokinetic parameters of half-life (t<sub>1/2</sub>, h), time until maximum concentration is reached (t<sub>max</sub>, h), maximum compound concentration (C<sub>max</sub>, ng/mL), and area under the curve (AUC, h.ng/mL) were determined. The experiments performed in this section were approved by the Committee on the Use of Laboratory Animals of the Oswaldo Cruz Foundation (CEUA-FIOCRUZ, license L003/21).</p>
</sec>
<sec id="S10">
<label>2.8</label>
<title>
<italic>In vivo</italic> assays – Mice treatment and infections</title>
<p id="P15">Experiments with transgenic mice expressing human ACE-2 receptor (K18-hACE2- mice), were performed in Animal Biosafety Level 3 (ABSL-3) multiuser facility, according to the animal welfare guidelines of the Ethics Committee of Animal Experimentation (CEUA-INCa, License 005/2021) and WHO guidelines [<xref ref-type="bibr" rid="R14">14</xref>]. The animals were obtained from the Oswaldo Cruz Foundation breeding colony and maintained with free access to food and water at 29–30°C under a controlled 12 h light/dark cycle. Experiments were performed during the light phase of the cycle.</p>
<p id="P16">For infection procedures, mice were anaesthetized with 60 mg/kg of ketamine and 4 mg/kg of xylazine and inoculated intranasally with DMEM high glucose (MOCK), or 10<sup>5</sup> PFU of SARS-CoV-2 gamma strain in 10 μl of DMEM high glucose. It was used 6 mice per experimental group: MOCK (non-infected); SARS-CoV-2-infected without treatment (NIL) and SARS-CoV-2-infected and treated with ATV. The animals were treated with a daily dose of 60 mg/kg of ATV for seven days.</p>
<p id="P17">The animals were monitored daily during seven days for survival and body-weight analysis. In the case of weight loss higher than 20% euthanasia was performed to alleviate animal suffering. In the last day, the bronchoalveolar lavage (BAL) from both lungs was harvested by washing the lungs once with 1 mL of cold PBS. After centrifugation of BAL (1500 rpm for 5 minutes), the pellet was used for total and differential leukocytes counts (diluted in Turk’s 2% acetic acid fluid) using a Neubauer chamber. The lactate dehydrogenase (LDH) quantification was performed with centrifuged BAL supernatant to evaluated cell death (CytoTox96, Promega, USA). Differential cell counts were performed by cytospin (Cytospin3; centrifugation of 350xg for 5 minutes at room temperature) and stained by the May-Grünwald-Giemsa method.</p>
<p id="P18">After BAL harvesting, lungs were perfused with 20 mL of saline solution to remove the circulating blood. Lungs were then collected, pottered, and homogenized in 500 μL of a phosphatase and protease inhibitor cocktail Complete, mini EDTA-free Roche Applied Science (Mannheim, Germany) for 30 sec, using an Ultra-Turrax Disperser T-10 basic IKA (Guangzhou, China).</p>
</sec>
<sec id="S11">
<label>2.9</label>
<title>Quantification of viral RNA</title>
<p id="P19">The viral RNA from samples collected in the <italic>in vivo</italic> assays was quantified through quantitative reverse transcription polymerase chain reaction (RT-PCR). Total RNA was extracted using QIAamp Viral RNA (Qiagen), according to manufacturer’s instructions. Quantitative RT-PCR was performed using Quanti Tect Probe RT-PCR Kit (Qiagen) in a StepOne Plus™ Real-Time PCR System (Thermo Fisher Scientific). Amplifications were carried out in 15 μL reaction mixtures containing 2× reaction mix buffer, 50 μM of each primer, 10 μM of the probe, and 5 μL of RNA template. Primers, probes, and cycling conditions recommended by the Centers for Disease Control and Prevention (CDC) protocol were used to detect the SARS-CoV-2 (CDC 2020). Amplification of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a reference for the number of cells. The cycle threshold (CT) values for this target were compared to those obtained with different cell quantities (10<sup>7</sup> to 10<sup>2</sup>), for calibration.</p>
</sec>
<sec id="S12">
<label>2.10</label>
<title>Measurements of inflammatory mediators and cell death</title>
<p id="P20">The levels of IL-6, TNF-α, KC, and PF4 were quantified in BAL samples from uninfected (MOCK), infected without treatment (NIL), and infected and treated animals by ELISA, using specific kits and following the manufacturer’s instructions (R&amp;D Systems). Cell death was determined according to the activity of LDH in the BAL as previously described in the <xref ref-type="sec" rid="S9">section 2.7</xref>.</p>
</sec>
<sec id="S13">
<label>2.11</label>
<title>Histological procedure</title>
<p id="P21">Histological features related to the injury caused by SARS-CoV-2 infection were analyzed in the lungs of K18-hACE2 mice. Inflammatory and vascular infiltrates and evidence of cell degeneration was evaluated to characterize the level of the tissue damage. The collected material was fixed with formaldehyde (4%), dehydrated and embedded in paraffin to the obtention of tissue slices through the use of a microtome. The slices were fixed and stained with hematoxylin and eosin for microphotographs analysis.</p>
</sec>
<sec id="S14">
<label>2.12</label>
<title>Clotting time</title>
<p id="P22">Human blood samples were collected from healthy donors in 3.8% trisodium citrate (9:1, v/v), and platelet-poor plasma was obtained by centrifugation at 3,000 rpm for 10 min. Plasma (100 μL) was incubated with 1 μL of ATV at various concentrations (diluted in DMSO) for 2 min at 310K. Plasma clotting was initiated by the addition of 100 μL of 25 mM CaCl2, and the time for clot formation was recorded on a KC-4 Delta coagulometer (Tcoag, Ireland). Time for clot formation was recorded in triplicates.</p>
</sec>
</sec>
<sec id="S15" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="S16">
<label>3.1</label>
<title>Enzymatic and cell-based assays for ATV in SARS-CoV-2 D614G and gamma strains</title>
<p id="P23">To advance on details on how ATV inhibits SARS-CoV-2 M<sup>pro</sup>, we initially performed a dose-dependent inhibition curve. ATV was slightly less potent than the positive control boceprevir (GC376) [<xref ref-type="bibr" rid="R24">24</xref>] (<xref ref-type="fig" rid="F1">Figure 1A</xref>). The Morrison’s inhibitory constant (Ki) values for GC376 and ATV were 208 ± 0.15 and 703 ± 79 nM, respectively. Next, we tested ATV against various concentrations of M<sup>pro</sup> substrate. We observed that maximum velocity (V<sub>max</sub>) values in the presence and absence of ATV were not different, while the Michaelis-Menten constant (K<sub>m</sub>) values increased significantly in the presence of this drug (<xref ref-type="fig" rid="F1">Figure 1B</xref>), indicating a competitive inhibition profile. Our results are specific to M<sup>pro</sup> because, differently from the positive control GRL0617, ATV did not inhibit SARS-CoV-2 papain-like protease (PL<sup>pro</sup>) (<xref ref-type="fig" rid="F1">Figure 1C</xref>). Since structural improvements on the M<sup>pro</sup> active site were determined more recently [<xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R26">26</xref>], SARS-CoV-2 molecular docking calculations were carried out to test if a catalytic water (H<sub>2</sub>O<sub>cat</sub>) was required for ATV action. Since the highest docking score value was obtained in the presence of H<sub>2</sub>O<sub>cat</sub>, molecular docking calculation suggested a dependence of ATV potency of water content into the catalytic site of M<sup>pro</sup> (<xref ref-type="fig" rid="F1">Figure 1D</xref>).</p>
<p id="P24">The competitive inhibition implies that M<sup>pro</sup>’s substrate concentration may affect its susceptibility to ATV. Thus, we tested if ATV’s potency is also affected in type II pneumocyte cell line (Calu-3) infected with different SARS-CoV-2 MOIs. In cell-based assays, the intracellular concentration of M<sup>pro</sup>’s substrate would be proportional to the virus input. Indeed, ATV’s EC<sub>50</sub> value for the SARS-CoV-2 B.1 lineage varied in a MOI-dependent way (<xref ref-type="table" rid="T1">Table 1</xref>), similarly to remdesivir (RDV) (<xref ref-type="table" rid="T1">Table 1</xref>), a competitive inhibitor of the SARS-CoV-2 RNA polymerase complex under clinical use [<xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R28">28</xref>]. The SARS-CoV-2 gamma VoC is more susceptible to ATV and RDV than its predecessor strain B.1 (<xref ref-type="table" rid="T1">Table 1</xref>). Since the CC<sub>50</sub> values of 312 ± 8 and 512 ± 30 μM for ATV and RDV, respectively, their selective index (SI) values were consistent with an adequate safety profile <italic>in vitro</italic> (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
</sec>
<sec id="S17">
<label>3.2</label>
<title>
<italic>In vivo</italic> antiviral activity of ATV against SARS-CoV-2 gamma variant</title>
<p id="P25">We first aimed evaluate ATV´s pharmacokinetics profile over time in the plasma and lungs of Swiss-Webster mice treated with 60 mg/kg of this drug, a dosage equivalent to its plasma exposure in humans under treatment against HIV. Upon treatment with 60 mg/kg, ATV concentration in the plasma was similar to the standard treatment of 300 mg in humans (<xref ref-type="fig" rid="F2">Figure 2A</xref>) [<xref ref-type="bibr" rid="R29">29</xref>]. Interestingly, ATV seems to be concentrated in the lung of the treated animals (<xref ref-type="fig" rid="F2">Figure 2B</xref>).</p>
<p id="P26">Next, we infected K18-hACE2-transgenic mice with SARS-CoV-2 gamma VoC and treated them with a daily oral dose of 60 mg/kg ATV, initiating 12h after infection. Whereas the infection kills all animals within 6 days, a statistically significant increase in animal survival was observed in the infected and ATV-treated mice (<xref ref-type="fig" rid="F3">Figure 3A</xref>). ATV protected the mice to continue to lose weight at the 6<sup>th</sup> day after infection (<xref ref-type="fig" rid="F3">Figures 3B</xref>). In the bronchoalveolar lavage (BAL) of the treated animals, ATV significantly decreased SARS-CoV-2 RNA levels (<xref ref-type="fig" rid="F3">Figure 3C</xref>), cell death - based on lactate dehydrogenase (LDH) activity (<xref ref-type="fig" rid="F3">Figure 3D</xref>), and cell-based inflammation – based on cells counts of polymorphonuclear and mononuclear cells (<xref ref-type="fig" rid="F3">Figure 3E and F</xref>).</p>
<p id="P27">ATV reduced the SARS-CoV-2-induced IL-6 levels in the BAL and in the lungs of treated animals (<xref ref-type="fig" rid="F4">Figure 4</xref>). In the lung, levels of TNF-α and KC were also reduced in the infected/untreated over untreated mice (<xref ref-type="fig" rid="F4">Figure 4</xref>). These results are in line with our previous description that ATV decreases the levels of SARS-CoV-2-induced proinflammatory cytokines in monocytes [<xref ref-type="bibr" rid="R7">7</xref>] and virus-triggered pyroptosis [<xref ref-type="bibr" rid="R30">30</xref>]. Moreover, SARS-CoV-2 infection provoked severe lung injury, leading to hemorrhage, and shrinking of the lobe, bronchiole, and alveoli (<xref ref-type="fig" rid="F5">Figure 5</xref>), which was reduced by ATV. This protection is the consequence of the direct antiviral and anti-inflammatory activity of ATV, since this molecule could not prevent hemorrhage as an anti-clotting agent (<xref ref-type="supplementary-material" rid="SD1">Figure S1</xref>, Supplementary Material).</p>
</sec>
</sec>
<sec id="S18" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p id="P28">Repurposing of clinically approved drugs was considered an accelerated strategy to combat SARS-CoV-2 infections [<xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R32">32</xref>]. However, limited clinical benefit has been documented for most repurposed drugs, whereas in the meantime orally available antiviral drugs against COVID-19 demonstrated clinical efficacy to reduce hospitalization, such as molnupiravir [<xref ref-type="bibr" rid="R33">33</xref>] and PAXLOVID™ [<xref ref-type="bibr" rid="R12">12</xref>]. Molnupiravir and PAXLOVID™ respectively target the viral RNA synthesis and M<sup>pro</sup>. Besides detailed mechanism of action, these compounds fulfilled pre-clinical steps of investigation, from cell-based to animal models, to allow further clinical development to be conducted at target plasmatic concentration. Here, we performed these steps for ATV. The comprehension that ATV inhibits competitively M<sup>pro</sup> and requires a catalytic water may allow further development of anti-SARS-CoV-2 analogs, that act differently than PAXLOVID™, a covalent inhibitor of M<sup>pro</sup> by interaction with the catalytic cysteine (Cys-145) residue [<xref ref-type="bibr" rid="R34">34</xref>].</p>
<p id="P29">We originally demonstrated that ATV inhibited SARS-CoV-2 M<sup>pro</sup> preparations and virus replication [<xref ref-type="bibr" rid="R7">7</xref>]. The controversial effects of ATV on SARS-CoV-2 M<sup>pro</sup> are documented in the literature [<xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R12">12</xref>]. In line with studies that demonstrated SARS-Cov-2 susceptibility to ATV, we demonstrated here that M<sup>pro</sup> was inhibited by this drug, with K<sub>i</sub> 1.5-fold higher than boceprevir (GC376) and in a competitive fashion, increasing the enzyme’s K<sub>m</sub> more than 6-fold. It is unlikely that the other SARS-CoV-2 protease, PL<sup>pro</sup>, was targeted by ATV in these assays, because its K<sub>i</sub> for PL<sup>pro</sup> was above the threshold of <italic>in vitro</italic> inhibition.</p>
<p id="P30">The amino acid residue His-41 of M<sup>pro</sup> requires water to catalyze proteolytic cleavage [<xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R26">26</xref>] and ATV targets this moiety. The presence of 20% glycerol in enzyme assay mixture reduces the water content and prevents ATV activity, that is why Ma and Wang [<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R35">35</xref>] could not identify this HIV protease inhibitor as a potential antiviral against COVID-19 - whereas Li et al. [<xref ref-type="bibr" rid="R10">10</xref>] reached results similarly to ours. Our enzymatic assay includes bovine serum albumin (BSA) to avoid non-specific binding of small molecules to M<sup>pro</sup>. In our M<sup>pro</sup> FRET-based enzymatic assay, reactions were allowed to occur overnight to increase the sensitivity, instead of 1h [<xref ref-type="bibr" rid="R13">13</xref>]. Although one might argue that a longer reaction time will increase the rate of false positive results, the following cell-based assays provide an additional layer of evidence that ATV activity against SARS-CoV-2 is credible.</p>
<p id="P31">Considering the substrate-dependent inhibitory effect of ATV, we hypothesized ATV’s potency in cell-based assays would be influenced by varying the virus input, because higher numbers of virus particles should translate into increased quantities of M<sup>pro</sup> substrate. To test this hypothesis, Calu-3 cells, which is more closely resemble type II pneumocytes than A549 and Vero cells [<xref ref-type="bibr" rid="R36">36</xref>], were infected with a 100-fold different multiplicity of infections (MOI) of SARS-CoV-2, B.1 lineage, and treated with ATV or RDV, a competitive inhibitor of viral RNA synthesis. The MOI-dependent inhibition was consistent for ATV and RDV. The similarity in the cell-based potency of ATV to its K<sub>i</sub> for M<sup>pro</sup> further reinforces the conclusion that M<sup>pro</sup> is the target of ATV <italic>in vitro</italic>.</p>
<p id="P32">The emerging Brazilian SARS-CoV-2 gamma variant, initially detected in the state of Amazonas, was responsible for a public health calamity, spreading rapidly in Brazil and considered as one of variant of concern by WHO. The mutations found in gamma variant have been associated with increased transmissibility, higher viral load, propensity for immune evasion, and SARS-CoV-2 reinfection [<xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R38">38</xref>]. ATV presented adequate inhibitory profile against the predecessor strain of SARS-CoV-2 and also the gamma variant <italic>in vitro</italic>. Based on that and considering the lethality of gamma variant on K-18 mice model, we next performed <italic>in vivo</italic> experiments.</p>
<p id="P33">At plasma exposures similar to humans [<xref ref-type="bibr" rid="R29">29</xref>], ATV enhanced by 30% the survival of K18-hACE2-transgenic mice infected with SARS-CoV-2 gamma strain and decreased virus-induced cell death and inflammation. Despite there is not a statical difference in the body weight between the untreated and treated groups, the protective effect of ATV was viewed in relation to the significantly decrease of SARS-CoV-2 RNA levels in the bronchoalveolar lavage (BAL), as well as a significant reduction in the number of mononuclear leukocytes, polymorphonuclear leukocytes and LDH levels. In the BAL infected and treated animals displayed lower levels of IL-6, TNF-α, KC and PF4, compared to untreated mice. The in vivo anti-inflammatory of ATV observed here is in line with the ability of this molecule to inhibit pyroptosis in human primary monocytes for both BAL and lung samples clearly showing that ATV protect both cell death and inflammation [<xref ref-type="bibr" rid="R39">39</xref>].</p>
<p id="P34">Our study shows that ATV inhibits SARS-COV-2 M<sup>pro</sup> with a mechanism of action different than PAXLOVID™, showing ATV/M<sup>pro</sup> interface could give insights for further drug development. The <italic>in vitro</italic> and <italic>in vivo</italic> results reconfirm, in different magnitudes, SARS-CoV-2 susceptibility to ATV. Further ongoing clinical trials will determine if standard dose, used in HIV-treatment can prevent severe COVID-19 or if it is necessary higher doses [<xref ref-type="bibr" rid="R40">40</xref>]. According to ATV’s monography [<xref ref-type="bibr" rid="R29">29</xref>], doses three times higher could be used for shorter periods of time, when compared to the life-lasting HIV treatment.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Material</label>
<media xlink:href="EMS140201-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="N66789" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S19">
<title>Acknowledgments</title>
<p>The authors acknowledgement the funding Brazilian agencies CNPq, Faperj, and CAPES and also Dra. Patricia Machado Rodrigues e Silva Martins and Dra Tatiana Paula Teixeira Ferreira from Fiocruz for the microphotographs analysis. O.A.C. also thanks Dr. Dumith Chequer Bou-Habib and Fundação para o Desenvolvimento Científico e Tecnológico em Saúde (FIOTEC) both from Oswaldo Cruz Foundation for the grant VPPCB-005-FIO-20.</p>
<sec id="S20">
<title>Funding</title>
<p>The project was financially supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ). This study was financed in part by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Brazil) with finance code 001.</p>
</sec>
</ack>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P35">
<bold>Author Contributions:</bold> Conceptualization, T.M.L.S. and P.T.B.; methodology, O.A.C., C.Q.S., A.C.F., M.M., N.F.-R., J.R.T., and T.M.L.S.; software, O.A.C.; validation, O.A.C., T.M.L.S., R.Q.M., P.T.B., H.C.C.-F.-N., and J.P.B.V.; formal analysis, O.A.C., C.Q.S., A.C.F., M.M., N.F.-R., J.R.T., D.P.P., G.P.E.S., L.B.F., H.M.P., A.S.C., J.C.d’Ávila, L.V., and R.Q.M.; investigation, O.A.C., T.M.L.S., C.Q.S., A.C.F., M.M., N.F.-R., and J.R.T.; resources, T.M.L.S., J.P.B.V., P.T.B., and H.C.C.-F.-N.; data curation, O.A.C. and T.M.L.S.; writing—original draft preparation, O.A.C. and T.M.L.S.; writing—review and editing, O.A.C., T.M.L.S., C.Q.S., A.C.F., M.M., N.F.-R., J.R.T., R.Q.M., J.P.B.V., and H.C.C.-F.-N.; visualization, O.A.C. and T.M.L.S.; supervision, T.M.L.S., R.Q.M., J.P.B.V., P.T.B., and H.C.C.-F.-N.; project administration, T.M.L.S.; funding acquisition, T.M.L.S., J.P.B.V., P.T.B., and H.C.C.-F.-N. All authors have read and agreed to the published version of the manuscript.</p>
</fn>
<fn id="FN2">
<p id="P36">
<bold>Institutional Review Board Statement:</bold> The <italic>in vivo</italic> studies were conducted according to the both guidelines of Committee on the Use of Laboratory Animals of the Oswaldo Cruz Foundation (CEUA-FIOCRUZ) with license L003/21 approved in 01/04/2020 and to the animal welfare guidelines of the Ethics Committee of Animal Experimentation from National Cancer Institute of Brazil (CEUA-INCA) with license 005/2021 approved in 03/05/2021.</p>
</fn>
<fn id="FN3">
<p id="P37">
<bold>Informed Consent Statement:</bold> Not applicable.</p>
</fn>
<fn id="FN4" fn-type="conflict">
<p id="P38">
<bold>Conflicts of Interest:</bold> The authors declare no conflict of interest and the funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaplin</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>COVID-19: A brief history and treatments in development</article-title>
<source>Prescriber</source>
<year>2020</year>
<volume>31</volume>
<fpage>23</fpage>
<lpage>28</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y-C</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>R-L</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>S-R</given-names>
</name>
</person-group>
<article-title>COVID-19: The first documented coronavirus pandemic in history</article-title>
<source>Biom J</source>
<year>2020</year>
<volume>43</volume>
<fpage>328</fpage>
<lpage>333</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="web">
<collab>WHO</collab>
<source>Coronavirus (COVID-19) Dashboard</source>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://covid19.who.int/">https://covid19.who.int/</ext-link>
</comment>
<date-in-citation>accessed on 06/11/2021</date-in-citation>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tregoning</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Flight</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Higham</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Pierce</surname>
<given-names>BF</given-names>
</name>
</person-group>
<article-title>Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape</article-title>
<source>Nat Rev Immunol</source>
<year>2021</year>
<volume>21</volume>
<fpage>626</fpage>
<lpage>636</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venkatesan</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Repurposing drugs for treatment of COVID-19</article-title>
<source>Lancet</source>
<year>2021</year>
<volume>9</volume>
<fpage>E63</fpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wood</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Atazanavir: its role in HIV treatment</article-title>
<source>Expert Rev Anti Infect Ther</source>
<year>2008</year>
<volume>6</volume>
<fpage>785</fpage>
<lpage>796</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fintelman-Rodrigues</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sacramento</surname>
<given-names>CQ</given-names>
</name>
<name>
<surname>Lima</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Mattos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Freitas</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Dias</surname>
<given-names>SSG</given-names>
</name>
<name>
<surname>Temerozo</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Miranda</surname>
<given-names>MD</given-names>
</name>
<etal/>
</person-group>
<article-title>Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production</article-title>
<source>Antimicrob Agents Chemother</source>
<year>2020</year>
<volume>64</volume>
<elocation-id>e00825-20</elocation-id>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="web">
<date-in-citation>accessed on 06/11/2021</date-in-citation>
<source>The Nitazoxanide Plus Atazanavir for COVID-19 Study (NACOVID)</source>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04459286">https://clinicaltrials.gov/ct2/show/NCT04459286</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="web">
<source>NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection (NATADEX)</source>
<date-in-citation>accessed on 06/11/2021</date-in-citation>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04452565?term=atazanavir&amp;cond=Covid-19&amp;draw=2&amp;rank=2">https://clinicaltrials.gov/ct2/show/NCT04452565?term=atazanavir&amp;cond=Covid-19&amp;draw=2&amp;rank=2</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual careening of existing drugs</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>2020</year>
<volume>117</volume>
<elocation-id>27381-27387</elocation-id>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors</article-title>
<source>Nature</source>
<year>2020</year>
<volume>582</volume>
<fpage>289</fpage>
<lpage>293</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="web">
<source>Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 Epic-HR Study</source>
<date-in-citation>accessed on 23/11/2021</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate">https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>2021</year>
<volume>118</volume>
<elocation-id>e2024420118</elocation-id>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bain</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Stitt-Fischer</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Practical guidelines for collection, manipulation and inactivation of SARS-CoV-2 and COVID-19 clinical specimens</article-title>
<source>Curr Protoc Cytom</source>
<year>2020</year>
<volume>93</volume>
<fpage>e77</fpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weglarz-Tomczak</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tomczak</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Talma</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Burda-Grabowska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giurg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brul</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Identifcation of ebselen and its analogues as potent covalente inhibitors of papain-like protease from SARS-CoV-2</article-title>
<source>Sci Rep</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>3640</elocation-id>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morse</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Lalonde</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>WR</given-names>
</name>
</person-group>
<article-title>Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV</article-title>
<source>Chembiochem</source>
<year>2020</year>
<volume>21</volume>
<fpage>730</fpage>
<lpage>738</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Curth</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Drosten</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sauerhering</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rox</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hilgenfeld</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors</article-title>
<source>Science</source>
<year>2020</year>
<volume>368</volume>
<fpage>409</fpage>
<lpage>412</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bafna</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Krug</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Montelione</surname>
<given-names>GT</given-names>
</name>
</person-group>
<article-title>Structural similarity of SARS-CoV2 Mpro and HCV NS3/4A proteases suggests new approaches for identifying existing drugs useful as COVID-19 therapeutics</article-title>
<source>ChemRxiv</source>
<year>2020</year>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="web">
<collab>Wavefunction, Inc</collab>
<date-in-citation>accessed on 06/11/2021</date-in-citation>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.wavefun.com/">https://www.wavefun.com/</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="web">
<source>GOLD: Protein-Ligand Docking Software</source>
<date-in-citation>accessed on 06/11/2021</date-in-citation>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.ccdc.cam.ac.uk/solutions/csd-discovery/components/gold/">http://www.ccdc.cam.ac.uk/solutions/csd-discovery/components/gold/</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="web">
<collab>PyMOL by Schrödinger</collab>
<date-in-citation>accessed on 06/11/2021</date-in-citation>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/">https://pymol.org/2/</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puhl</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Fritch</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Tse</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Yount</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Sacramento</surname>
<given-names>CQ</given-names>
</name>
<name>
<surname>Fintelman-Rodrigues</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tavella</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>FTM</given-names>
</name>
<name>
<surname>Weston</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Logue</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Repurposing the ebola and marburg virus inhibitors tilorone, quinacrine, and pyronaridine: In vitro activity against SARS-CoV-2 and potential mechanisms</article-title>
<source>ACS Omega</source>
<year>2021</year>
<volume>6</volume>
<fpage>7454</fpage>
<lpage>7468</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sacramento</surname>
<given-names>CQ</given-names>
</name>
<name>
<surname>Fintelman-Rodrigues</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Temerozo</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>APD</given-names>
</name>
<name>
<surname>Días</surname>
<given-names>SSG</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Mattos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pão</surname>
<given-names>CRR</given-names>
</name>
<name>
<surname>de Freitas</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>VC</given-names>
</name>
<etal/>
</person-group>
<article-title>In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the etiological agent of COVID-19</article-title>
<source>J Antimicrob Chemother</source>
<year>2021</year>
<volume>76</volume>
<fpage>1874</fpage>
<lpage>1885</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oerlemans</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ruiz-Moreno</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Cong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Velasco-Velazquez</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Neochoritis</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Reggiori</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Groves</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Domling</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics</article-title>
<source>RSC Med Chem</source>
<year>2021</year>
<volume>12</volume>
<fpage>370</fpage>
<lpage>379</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kneller</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>G</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Jedrzejczak</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Stols</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Langan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Joachimiak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Coates</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kovalevsky</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography</article-title>
<source>Nature Comm</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>3202</elocation-id>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Worrall</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Vuckovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rosell</surname>
<given-names>FI</given-names>
</name>
<name>
<surname>Gentile</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ton</surname>
<given-names>A-T</given-names>
</name>
<name>
<surname>Caveney</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Ban</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cherkasov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Paetzel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Strynadka</surname>
<given-names>NCJ</given-names>
</name>
</person-group>
<article-title>Crystallographic structure of wild-type SARS-CoV2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site</article-title>
<source>Nature Comm</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>5877</elocation-id>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kokic</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hillen</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Tegunov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dienemann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Seitz</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schmitzova</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Farnung</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Siewert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hobartner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cramer</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Mechanism of SARS-CoV-2 polymerase stalling by remdesivir</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<fpage>279</fpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>395</volume>
<fpage>1569</fpage>
<lpage>1578</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="web">
<source>Product Monograph Atazanavir Capsules</source>
<date-in-citation>accessed on 6/11/2021</date-in-citation>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.bms.com/assets/bms/ca/documents/productmonograph/REYATAZ_EN_PM.pdf">https://www.bms.com/assets/bms/ca/documents/productmonograph/REYATAZ_EN_PM.pdf</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreira</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>de Azevedo-Quintanilha</surname>
<given-names>IG</given-names>
</name>
<name>
<surname>Dias</surname>
<given-names>SSG</given-names>
</name>
<name>
<surname>Fintelman-Rodrigues</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sacramento</surname>
<given-names>CQ</given-names>
</name>
<name>
<surname>Mattos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Freitas</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Temerozo</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hottz</surname>
<given-names>ED</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes</article-title>
<source>Cell Death Discov</source>
<year>2021</year>
<volume>7</volume>
<fpage>43</fpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trezza</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lovinelli</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Santucci</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Prischi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Spiga</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors</article-title>
<source>Sci Rep</source>
<year>2020</year>
<volume>10</volume>
<elocation-id>13866</elocation-id>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrade</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Rangel</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>NO</given-names>
</name>
<name>
<surname>Freitas</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>WRA</given-names>
</name>
<name>
<surname>Siqueira</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barh</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Góes-Neto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Birbrair</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Azevedo</surname>
<given-names>VAC</given-names>
</name>
</person-group>
<article-title>Repurposing approved drugs for guiding COVID-19 prophylaxis: A systematic review</article-title>
<source>Front Pharmacol</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>590598</elocation-id>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="web">
<source>Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study</source>
<date-in-citation>accessed on 23/11/2021</date-in-citation>
<comment>[CrossRef] <ext-link ext-link-type="uri" xlink:href="https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/">https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pavan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bolcato</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bassani</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sturlese</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moro</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Supervised molecular dynamics (SuMD) insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332</article-title>
<source>J Enzyme Inhib Med Chem</source>
<year>2021</year>
<volume>36</volume>
<fpage>1646</fpage>
<lpage>1650</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sacco</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Hurst</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Townsend</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Szeto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tarbet</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Marty</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease</article-title>
<source>Cell Res</source>
<year>2020</year>
<volume>30</volume>
<fpage>678</fpage>
<lpage>692</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mösbauer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hofmann-Winkler</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kaul</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kleine-Weber</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kruger</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gassen</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Drosten</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pohlmann</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>585</volume>
<fpage>588</fpage>
<lpage>590</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nonaka</surname>
<given-names>CKV</given-names>
</name>
<name>
<surname>Graf</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Barcia</surname>
<given-names>CAL</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Passos</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Bastos</surname>
<given-names>IN</given-names>
</name>
<name>
<surname>de Santana</surname>
<given-names>MCB</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>de Souza</surname>
<given-names>KAF</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>TGL</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021</article-title>
<source>Int J Infect Dis</source>
<year>2021</year>
<volume>111</volume>
<fpage>47</fpage>
<lpage>54</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faria</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Mellan</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Whittaker</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Claro</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Candido</surname>
<given-names>DDS</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Crispim</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Sales</surname>
<given-names>FCS</given-names>
</name>
<name>
<surname>Hawryluk</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mccrone</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Hulswit</surname>
<given-names>RJG</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>LAM</given-names>
</name>
<etal/>
</person-group>
<article-title>Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil</article-title>
<source>Science</source>
<year>2021</year>
<volume>372</volume>
<fpage>815</fpage>
<lpage>821</lpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreira</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>de Azevedo-Quintanilha</surname>
<given-names>IG</given-names>
</name>
<name>
<surname>Dias</surname>
<given-names>SSG</given-names>
</name>
<name>
<surname>Fintelman-Rodrigues</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sacramento</surname>
<given-names>CQ</given-names>
</name>
<name>
<surname>Mattos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Freitas</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Temerozo</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hottz</surname>
<given-names>ED</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes</article-title>
<source>Cell Death Discov</source>
<year>2021</year>
<volume>7</volume>
<fpage>43</fpage>
<comment>[CrossRef]</comment>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="web">
<source>Antiviral Agents Against COVID-19 Infection (REVOLUTIOn)</source>
<date-in-citation>accessed on 06/11/2021</date-in-citation>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04468087?term=Atazanavir&amp;cond=SARS-CoV+Infection&amp;draw=2&amp;rank=3">https://clinicaltrials.gov/ct2/show/NCT04468087?term=Atazanavir&amp;cond=SARS-CoV+Infection&amp;draw=2&amp;rank=3</ext-link>
</comment>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>(A) The ATV and boceprevir (GC376, positive control) activity on 88.8 nM M<sup>pro</sup> velocity at 0-10 μM of inhibitor (protease assay kit #79955-1, BPS Biosciences, USA). (B) Michaelis-Menten plot for 88.8 nM M<sup>pro</sup> incubated overnight in assay buffer with substrate concentrations from 0 to 100 μM in the presence and absence of 2.5 μM of ATV. (C) The ATV and GRL-617 (positive control) activity on 100 nM PL<sup>pro</sup> velocity at 0-10 μM of inhibitor (protease assay kit #79995-1, BPS Biosciences, USA). (D) The 3D representation of the best docking pose for ATV into M<sup>pro</sup> catalytic site in the presence of the catalytic water (H<sub>2</sub>O<sub>cat</sub>) obtained with GOLD 2020.2 software (Cambridge Crystallographic Data Centre, Cambridge, CB2 1EZ, UK) using ChemPLP as scoring function. For better interpretation the M<sup>pro</sup> structure was represented only in the monomeric form with the domains I, II, and III in light red orange, and gray, respectively. The ATV and catalytic amino acid residues are in stick representation in pink and cyan, respectively, while H<sub>2</sub>O<sub>cat</sub> is represented as sphere.</p>
</caption>
<graphic xlink:href="EMS140201-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Pharmacokinetics of atazanavir (ATV) in mice. Swiss-Webster mice at 8-15 weeks of age were orally treated with 60 mg/kg of ATV. (A) At indicated time points, concentration of ATV was measured in the plasma and in the lungs. The insert in panel A represents the pharmacokinetic parameters in the plasma. (B) The area under the curve (AUC) for the anatomical compartments were registered.</p>
</caption>
<graphic xlink:href="EMS140201-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>ATV protected K18-hACE2-transgenic mice infected with SARS-CoV-2 from mortality.</title>
<p>The survival (A), and weight variation (B) of the different experimental groups: non-infected and non-treated (MOCK) or SARS-CoV-2-infected and non-treated (NIL) SARS-CoV-2-infected and treated with ATV. After 12h of infection the treated group received the first of a daily dose of 60 mg/kg of ATV. The animals were treated for six days. Survival was statistically assessed by Log-rank (Mentel-Cox) test, where * p &lt; 0.05. The viral load (C), LDH levels (D), polymorphonuclear and mononuclear cells counts (E) and immunocytochemical staining (F) were assessed in the BAL six days after infection in the indicated experimental groups. All the analysis were performed with 6 mice/group.</p>
</caption>
<graphic xlink:href="EMS140201-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<title>The proinflammatory content in terms of cytokines IL-6, TNF-α, KC, and PF4 in BAL and lung samples. * p &lt; 0.05</title>
</caption>
<graphic xlink:href="EMS140201-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<title>Microphotographs for histology of lung lobe, bronchiole, and alveoli samples from K18-hACE2-transgenic mice non-infected (MOCK) and infected with SARS-CoV-2 gamma strain without (NIL) and treated with ATV upon the six treated days.</title>
</caption>
<graphic xlink:href="EMS140201-f005"/>
</fig>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<title>
<italic>In vitro</italic> pharmacological parameters for ATV and RDV against SARS-CoV-2 variants in Calu-3 cells.</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr style="border-bottom: solid 0.01em;">
<th align="center" valign="top"/>
<th align="center" valign="top"/>
<th align="center" valign="top" colspan="3">ATV</th>
<th align="center" valign="top" colspan="3">RDV</th>
</tr>
<tr>
<th align="center" valign="top">Strain</th>
<th align="center" valign="top">MOI</th>
<th align="center" valign="top">EC<sub>50</sub> (μM)</th>
<th align="center" valign="top">CC<sub>50</sub> (μM)</th>
<th align="center" valign="top">SI</th>
<th align="center" valign="top">EC<sub>50</sub> (μM)</th>
<th align="center" valign="top">CC<sub>50</sub> (μM)</th>
<th align="center" valign="top">SI</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="top">B.1</td>
<td align="center" valign="top">0.1</td>
<td align="center" valign="top">0.490 ± 0.020</td>
<td align="center" valign="middle" rowspan="3" style="writing-mode:tb-rl;writing-mode:vertical-rl;">312 ± 8</td>
<td align="center" valign="top">637</td>
<td align="center" valign="top">0.461 ± 0.038</td>
<td align="center" valign="middle" rowspan="3" style="writing-mode:tb-rl;writing-mode:vertical-rl;">512±30</td>
<td align="center" valign="top">1,111</td>
</tr>
<tr>
<td align="center" valign="top">B.1</td>
<td align="center" valign="top">0.001</td>
<td align="center" valign="top">0.321 ± 0.016</td>
<td align="center" valign="top">972</td>
<td align="center" valign="top">0.225 ± 0.019</td>
<td align="center" valign="top">2,276</td>
</tr>
<tr>
<td align="center" valign="top">P1 (formally B.1.1.28)</td>
<td align="center" valign="top">0.1</td>
<td align="center" valign="top">0.399 ± 0.020</td>
<td align="center" valign="top">782</td>
<td align="center" valign="top">0.113 ± 0.010</td>
<td align="center" valign="top">4,530</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
